Company Quick10K Filing
GW Pharmaceuticals
10-K 2019-12-31 Filed 2020-02-27
10-Q 2019-09-30 Filed 2019-11-06
10-Q 2019-06-30 Filed 2019-08-07
10-Q 2019-03-31 Filed 2019-05-08
10-K 2018-09-30 Filed 2018-11-29
20-F 2017-09-30 Filed 2017-12-04
20-F 2016-09-30 Filed 2016-12-05
20-F 2014-09-30 Filed 2014-12-04
20-F 2013-09-30 Filed 2013-11-25
8-K 2020-02-25 Earnings, Exhibits
8-K 2020-02-03 Other Events, Exhibits
8-K 2020-01-12 Earnings, Exhibits
8-K 2019-11-05 Earnings, Exhibits
8-K 2019-09-23 Regulation FD, Exhibits
8-K 2019-08-06 Earnings, Exhibits
8-K 2019-07-26 Other Events, Exhibits
8-K 2019-06-13 Regulation FD, Exhibits
8-K 2019-06-13 Shareholder Vote
8-K 2019-05-06 Earnings, Other Events, Exhibits
8-K 2019-04-10 Officers, Other Events, Exhibits
8-K 2019-04-05 M&A
8-K 2019-03-15 Enter Agreement, M&A, Other Events, Exhibits
8-K 2019-02-26 Earnings, Exhibits
8-K 2019-01-07 Regulation FD, Exhibits
8-K 2018-11-27 Earnings, Officers, Exhibits
8-K 2018-11-26 Other Events, Exhibits
8-K 2018-10-02 Enter Agreement, Other Events, Exhibits
8-K 2018-10-01 Other Events, Exhibits

GW Pharmaceuticals Financials

GWPH Metrics, Comps, Filings

Quarterly | Annual

Business

We are a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from our proprietary cannabinoid product platform in a broad range of disease areas. In our 20 years of operations, we have established a world leading position in the development of plant-derived cannabinoid therapeutics through our proven drug discovery and development processes, our intellectual property portfolio and regulatory and manufacturing expertise. Our lead cannabinoid product is Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD), for which we retain global commercial rights. Epidiolex was approved by the FDA on June 25, 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome, or LGS, or Dravet syndrome, in patients two years of age and older. LGS and Dravet syndrome are severe childhood-onset, drug-resistant epilepsy syndromes. On September 28, 2018, the Drug Enforcement Agency (DEA) placed Epidiolex in Schedule V, the lowest restriction classification. Epidiolex became commercially available in the U.S. on November 1, 2018.

In Europe, we submitted an application for Epidiolex to the European Medicines Agency's, or EMA's, Committee for Medical Products for Human Use (CMPH) in December 2017, and we expect a decision on the application in the first quarter of 2019. We have received Orphan Drug Designation from the FDA for Epidiolex for LGS, Dravet syndrome and tuberous sclerosis complex, (TSC). We also received Orphan Designation from the EMA's Committee for Orphan Medical Products (COMP) for Epidiolex for Dravet syndrome, LGS, and TSC. We continue to develop Epidiolex for additional indications, including the treatment of seizures associated with TSC and plan to commence a pivotal trial in the treatment of Rett syndrome.

Previously, we developed the world's first plant-derived cannabinoid prescription drug, Sativex (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the U.S. In the U.S., we have full commercial rights to this product and plan to meet with the FDA in the fourth quarter 2018 to discuss data from the completed Phase 3 trials in Europe and determine the optimal regulatory pathway.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Quarterly)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Eli Lilly (LLY) 105,897 78% 12.7 21% 37,893 34,431 22,644 17,612 7,948 9,419 119,560
AbbVie (ABBV) 109,786 77% 21.1 5% 59,441 67,667 32,867 25,412 3,255 6,259 132,264
Beigene (BGNE) 100,124 74% -123.1 -44% 1,881 587 430 318 -827 -807 99,328
Bristol Myers Squibb (BMY) 82,160 70% 10.6 10% 57,433 39,679 24,173 16,837 5,680 7,151 76,061
Celgene (CELG) 72,111 96% 10.4 14% 41,363 29,276 16,982 16,354 5,880 7,734 80,796
GW Pharmaceuticals (GWPH) 45,954 89% -870.1 -8% 848 128 205 182 -64 -52 45,400
Allergan (AGN) 54,957 63% -241.2 -5% 122,925 38,486 15,818 9,949 -5,872 -316 76,270
Zoetis (ZTS) 60,799 51% 29.1 13% 11,272 8,594 6,150 3,124 1,461 2,252 65,484
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 43,431 87% 46.7 29% 7,515 2,261 3,620 3,135 2,144 857 40,027
Regeneron Pharmaceuticals (REGN) 32,266 0% 12.2 15% 13,939 3,435 7,622 0 2,144 2,539 30,869
Alexion Pharmaceuticals (ALXN) 23,581 92% 12.8 10% 14,815 4,448 4,736 4,359 1,470 1,874 23,912
Biomarin Pharmaceutical (BMRN) 12,700 79% 1,194.1 -1% 4,558 1,484 1,250 986 -39 11 13,147
Elanco Animal Health (ELAN) 9,964 52% 30.6 1% 8,824 3,336 3,083 1,611 94 393 12,004
Mylan (MYL) 10,768 34% 12.5 -0% 31,054 19,590 8,309 2,810 -4 1,882 23,458
Teva (TEVA) 7,142 43% -10.6 -7% 57,246 42,322 17,455 7,550 -3,961 -2,814 29,713
Sarepta Therapeutics (SRPT) 5,588 0% -7.9 -36% 1,702 707 365 0 -620 -576 4,529
Ionis Pharmaceuticals (IONS) 8,784 76% 17.4 15% 2,895 1,397 821 626 436 491 8,536
Sage Therapeutics (SAGE) 7,414 82% -10.7 -56% 1,204 123 5 4 -670 -670 7,152
Bausch (BHC) 7,760 0% 25.3 -1% 31,667 29,107 8,498 0 -266 1,216 30,774

Balance Sheet ($MM)2018-09-302019-03-312019-06-302019-09-30
Cash355522584555
Accounts Receivable2193242
Inventory19496069
PP&E110134140144
Assets491750843848
Accounts Payable1011127
Long-Term Debt
Liabilities75110114128
Stockholders' Equity415640729720
Income Statement ($MM)2018-09-302019-03-312019-06-302019-09-30
Revenue2397291
Cost of Revenue578
Gross Profit346583
R&D303236
SG&A556264
Tax04-0
Net Income-80-5080-14
Cash Flow ($MM)2018-09-302019-03-312019-06-302019-09-30
Cash Operating-58-31-18
Cash Investing-1293-8
Cash Financing02-0